These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 34624086)
1. An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa--authors' response. Isler B; Harris P; Stewart AG; Paterson DL J Antimicrob Chemother; 2021 Nov; 76(12):3327-3328. PubMed ID: 34624086 [No Abstract] [Full Text] [Related]
2. Comment on: An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa. Nicolau DP; Bhagwat SS; Abdelraouf K J Antimicrob Chemother; 2021 Nov; 76(12):3326-3327. PubMed ID: 34179957 [No Abstract] [Full Text] [Related]
3. An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa. Isler B; Harris P; Stewart AG; Paterson DL J Antimicrob Chemother; 2021 Feb; 76(3):550-560. PubMed ID: 33332545 [TBL] [Abstract][Full Text] [Related]
4. In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria. Abdelraouf K; Almarzoky Abuhussain S; Nicolau DP J Antimicrob Chemother; 2020 Dec; 75(12):3601-3610. PubMed ID: 32862218 [TBL] [Abstract][Full Text] [Related]
7. VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Hamrick JC; Docquier JD; Uehara T; Myers CL; Six DA; Chatwin CL; John KJ; Vernacchio SF; Cusick SM; Trout REL; Pozzi C; De Luca F; Benvenuti M; Mangani S; Liu B; Jackson RW; Moeck G; Xerri L; Burns CJ; Pevear DC; Daigle DM Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871094 [TBL] [Abstract][Full Text] [Related]
8. Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria. Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM Int J Antimicrob Agents; 2021 May; 57(5):106318. PubMed ID: 33716176 [TBL] [Abstract][Full Text] [Related]
9. In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model. Gill CM; Abdelraouf K; Nicolau DP J Antimicrob Chemother; 2021 Mar; 76(4):993-1000. PubMed ID: 33438033 [TBL] [Abstract][Full Text] [Related]
10. Activity of cefepime, ceftazidime, and ceftizoxime against mutants of Enterobacteriaceae and Pseudomonas aeruginosa derepressed for class I beta-lactamase. Knapp CC; Washington JA J Antimicrob Chemother; 1989 Dec; 24(6):1011-2. PubMed ID: 2516083 [No Abstract] [Full Text] [Related]
11. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa. Watanabe N; Hiruma R; Katsu K J Antimicrob Chemother; 1992 Nov; 30(5):633-41. PubMed ID: 1493980 [TBL] [Abstract][Full Text] [Related]
12. Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa. Drusano GL; Bonomo RA; Bahniuk N; Bulitta JB; Vanscoy B; Defiglio H; Fikes S; Brown D; Drawz SM; Kulawy R; Louie A Antimicrob Agents Chemother; 2012 Jan; 56(1):231-42. PubMed ID: 22005996 [TBL] [Abstract][Full Text] [Related]
13. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa. Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815 [TBL] [Abstract][Full Text] [Related]